Navigation Links
Rheumatoid Arthritis: World Drug Market 2011-2021
Date:11/2/2011

y (EMA/EMEA)

Food and Drug Administration (US FDA)

GE Healthcare

Genentech (owned by Roche)

Genmab

Genzyme (owned by Sanofi)

Gilead Sciences

GlaxoSmithKline (GSK)

Horizon Pharma

Human Genome Sciences

Imperial College London 

Incyte Corporation

Japanese Ministry of Health, Labour and Welfare

Johnson & Johnson

Kitasato University

Kobe University 

mAb Discovery

Medicare

Merck & Co.

Mitsubishi Tanabe Pharma

National Health Service (UK NHS) 

National Rheumatoid Arthritis Society (NRAS)

New York University

Novartis

Nycomed

Otsuka Pharmaceutical

Pfizer

PharmaNet Development Group

PLx Pharma

Radient Pharmaceuticals

ReceptoPharm

Regeneron

Rigel Pharmaceuticals

Roche

Rules-Based Medicine

Sanofi

Schering-Plough (now part of Merck and Co.)

SkyePharma

Teva

Takeda

Toyoma Chemical

Tragara Pharmaceuticals

UCB

World Health Organization (WHO)

Wyeth (now part of Pfizer)

Zenyaku Kogyo 

To order this report:

Pathology Industry: Rheumatoid Arthritis: World Drug Market 2011-2021

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
2. Rheumatoid Arthritis Market Forecast
3. HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis
4. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
5. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
6. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
7. Exagen Diagnostics Inc. Partners with Medco Research Institute® to Develop NIMBLE Personalized Medicine Program for Rheumatoid Arthritis Patients
8. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
9. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
10. Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
11. Reportlinker Adds Epidemiology: Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 15 Theranostics Health (TH) today,announced that ... Registration from the,Federal Government. This, along with ... Maryland Department of Health & Mental Hygiene, ... testing in the,disciplines/specialties of Immunology/protein microarray and,Pathology/histopathology., ...
... With Deep Vein, Thrombosis; $10 Million National ... Drug- Device Technique Can Prevent Post-Thrombotic Syndrome, FAIRFAX, ... trial of a catheter-based treatment for deep vein thrombosis,-- ... with clot,removal devices to prevent post-thrombotic syndrome in patients ...
Cached Medicine Technology:Theranostics Health Receives Green Light to Perform Clinical Testing 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 2Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 3Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs 4
(Date:1/22/2015)... 22, 2015 Deer Path of Huntley ... Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. on ... Parkway in Huntley, Illinois, serves adults with physical disabilities between the ... include Valentine's Day treats, games and sweetheart-themed karaoke. , For more ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... 25, 2011) -- A child,s taste preferences begin at home ... say, young kids learn quickly what brands deliver the goods. ... involving two separate experiments, researchers found that salt, sugar and ... children already could equate their taste preferences to brand-name fast-food ...
... HealthDay Reporter , MONDAY, Jan. 24 (HealthDay News) -- ... therapy may reduce the risk of heart attack, stroke and ... About 30 percent of heart attacks may be linked to ... problems, such as depression and hostility, the authors note in ...
... , MONDAY, Jan. 24 (HealthDay News) -- ... are not as strong as they think. In ... than strangers do, a new study suggests. ... friends than with strangers. That closeness can lead people ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 24 ... children fight obesity, a new study suggests. Too little ... conditions, but "catch-up" sleep on weekends and holidays can mitigate ... the United States, the sleep of our children is clearly ...
... Can optimism be ethically problematic? Yes, according to a ... in early-phase cancer trials and suggested that it may ... assume that hope and optimism in the research context ... they reflect a bias," write the authors of the ...
... By Dennis Thompson HealthDay Reporter , SUNDAY, ... of a mainstream approach to Americans, health woes. People ... serenity and wellness, but its roots in ancient Indian philosophy ... alternative medicine. However, a growing body of scientific ...
Cached Medicine News:Health News:Preschool kids know what they like: Salt, sugar and fat 2Health News:Preschool kids know what they like: Salt, sugar and fat 3Health News:Stress-Reduction Therapy May Help Heart Disease Patients 2Health News:Stress-Reduction Therapy May Help Heart Disease Patients 3Health News:Close Relationships Sometimes Mask Poor Communication 2Health News:Insufficient, Irregular Sleep Tied to Kids' Obesity 2Health News:Insufficient, Irregular Sleep Tied to Kids' Obesity 3Health News:Unrealistic optimism appears common in early cancer trials 2Health News:Yoga's Spiritual Balance May Boost Health 2Health News:Yoga's Spiritual Balance May Boost Health 3
... WristOx® 3100 is a small, ... be worn comfortably on the ... daily activities and for overnight ... the WristOx is intended to ...
... The PulseOx 5500TM is the ... blood oxygen saturation and heart rate ... The PulseOx 5500TM uses SPO Medicals ... device which is more usable for ...
All-in-One Fingertip Oximeter...
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
Medicine Products: